Latham & Watkins Advises Vera Therapeutics in US$500 Million Credit Facility With Oxford Finance

Vera Therapeutics, Inc. (Vera), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, has announced that it has entered into a new credit facility providing for up to US$500 million of term loans with its current partner Oxford Finance LLC (Oxford). The new credit facility will replace Vera’s existing US$50 million credit facility. The initial funding of the new credit facility will be in a principal amount of US$75 million and is expected to occur on June 4, 2025.

Latham & Watkins LLP represents Vera Therapeutics in the transaction with a finance deal team led by partner Haim Zaltzman, with associates Hai Pham, Alex Grossman, and Jake Ibrahim. Advice was provided on corporate matters by partners Keith Halverstam, Eric Rice, and Alex Kassai, with counsel Emily Corbi; and on tax matters by partner Eric Cho.